The role of early viral decline in the treatment of hepatitis C in HIV-1-coinfected persons [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 3, 2007, Pages 371-373

  Kang, Minhee ^a   Chung, Raymond T ^b  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

CLINICAL TRIAL; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER BIOPSY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; RECURRENCE; TREATMENT OUTCOME; VASCULAR RESISTANCE; VIRAL LOAD;

EID: 37349131919     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3180dec9fc     Document Type: Letter

References (8)

1. Laguno M, Larrousse M, Murillas J, et al. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. J Acquir Immune Defic Syndr. 2007;44:174-178.
2. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
3. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize longterm response among patients infected with genotype-1 hepatitis C virus. J Infect Dis. 2004;189:964-970.
4. Soriano V, Nunez M, Camino N, et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther. 2004;9:505-509.
5. Voigt E, Schulz C, Klausen G, et al. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. J Infect. 2006;53:36-42.
6. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
7. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005;42:615-624.
8. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451-460.